ArticleAnnals of medicine and surgery (2012)2025

Mavorixafor, CXCR4 antagonist, a novel treatment for WHIM syndrome, first FDA approval 2024.

Aiman Waheed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.